Severity of non-alcoholic fatty liver disease is associated with high systemic levels of tumor necrosis factor alpha and low serum interleukin 10 in morbidly obese patients

Clinical and Experimental Medicine

Volumn 16, Issue 2, 2016, Pages 193-202

  Paredes Turrubiarte, Gabriela ^a   González Chávez, Antonio ^a   Pérez Tamayo, Ruy ^b   Salazar Vázquez, Beatriz Y ^b   Hernández, Vito S ^b   Garibay Nieto, Nayeli ^a   Fragoso, José Manuel ^c   Escobedo, Galileo ^b  

^a HOSPITAL GENERAL DE MÉXICO   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^c INSTITUTO NACIONAL DE CARDIOLOGÍA IGNACIO CHÁVEZ   (Mexico)

Author keywords

Hepatic steatosis; Interleukin 10; Morbid obesity; NAFLD; Systemic inflammation; Tumor necrosis factor alpha

Indexed keywords

ASPARTATE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; GLYCOSYLATED HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN; INSULIN; INTERLEUKIN 10; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; IL10 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR;

ADULT; AGED; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN RESISTANCE; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; MORBID OBESITY; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; ADOLESCENT; BLOOD; CHEMISTRY; COMPLICATION; DIAGNOSTIC IMAGING; ECHOGRAPHY; LIVER; LIVER FUNCTION TEST; MIDDLE AGED; PATHOLOGY; SERUM; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; FEMALE; HUMANS; INTERLEUKIN-10; LIVER; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY, MORBID; SERUM; SEVERITY OF ILLNESS INDEX; TUMOR NECROSIS FACTOR-ALPHA; ULTRASONOGRAPHY; YOUNG ADULT;

EID: 84928137790     PISSN: 15918890     EISSN: 15919528     Source Type: Journal    
DOI: 10.1007/s10238-015-0347-4     Document Type: Article

References (64)

1. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: executive summary. Expert Panel on the Identification, Evaluation, and Treatment of Overweight in Adults. Am J Clin Nutr. 1998;68(4):899–917.
2. Popkin BM. Does global obesity represent a global public health challenge? Am J Clin Nutr. 2011;93(2):232–3. doi:10.3945/ajcn.110.008458.
3. Gutiérrez JP R-DJ, Shamah-Levy T, Villalpando-Hernández S, Franco A, Cuevas-Nasu L, Romero-Martínez M H-ÁM. Encuesta Nacional de Salud y Nutrición 2012. Resultados Nacionales. 2012.
4. Barquera S, Campos-Nonato I, Hernandez-Barrera L, Pedroza A, Rivera-Dommarco JA. Prevalence of obesity in Mexican adults 2000–2012. Salud Publica Mex. 2013;55(Suppl 2):S151–60.
5. Efthymiou V, Hyphantis T, Karaivazoglou K, Gourzis P, Alexandrides TK, Kalfarentzos F, et al. The effect of bariatric surgery on patient HRQOL and sexual health during a 1-year postoperative period. Obes Surg. 2014;. doi:10.1007/s11695-014-1384-x.
6. Kitahara CM, Flint AJ, Berrington de Gonzalez A, Bernstein L, Brotzman M, MacInnis RJ, et al. Association between class III obesity (BMI of 40–59 kg/m2) and mortality: a pooled analysis of 20 prospective studies. PLoS Med. 2014;11(7):e1001673. doi:10.1371/journal.pmed.1001673.
7. Rodriguez-Gallego E, Guirro M, Riera-Borrull M, Hernandez-Aguilera A, Marine-Casado R, Fernandez-Arroyo S, et al. Mapping of the circulating metabolome reveals alpha-ketoglutarate as a predictor of morbid obesity-associated non-alcoholic fatty liver disease. Int J Obes (Lond). 2014;. doi:10.1038/ijo.2014.53.
8. Bluher M. The distinction of metabolically ‘healthy’ from ‘unhealthy’ obese individuals. Curr Opin Lipidol. 2010;21(1):38–43. doi:10.1097/MOL.0b013e3283346ccc.
9. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD single topic conference. Hepatology. 2003;37(5):1202–19. doi:10.1053/jhep.2003.50193.
10. Paredes AH, Torres DM, Harrison SA. Nonalcoholic fatty liver disease. Clin Liver Dis. 2012;16(2):397–419. doi:10.1016/j.cld.2012.03.005.
11. Gholam PM, Flancbaum L, Machan JT, Charney DA, Kotler DP. Nonalcoholic fatty liver disease in severely obese subjects. Am J Gastroenterol. 2007;102(2):399–408. doi:10.1111/j.1572-0241.2006.01041.x.
12. Dixon JB, Bhathal PS, O’Brien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology. 2001;121(1):91–100.
13. Tran A, Gual P. Non-alcoholic steatohepatitis in morbidly obese patients. Clin Res Hepatol Gastroenterol. 2013;37(1):17–29. doi:10.1016/j.clinre.2012.07.005.
14. Adams LA, Sanderson S, Lindor KD, Angulo P. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol. 2005;42(1):132–8. doi:10.1016/j.jhep.2004.09.012.
15. Suarez-Alvarez K, Solis-Lozano L, Leon-Cabrera S, Gonzalez-Chavez A, Gomez-Hernandez G, Quinones-Alvarez MS, et al. Serum IL-12 is increased in Mexican obese subjects and associated with low-grade inflammation and obesity-related parameters. Mediators Inflamm. 2013;2013:967067. doi:10.1155/2013/967067.
16. Leon-Cabrera S, Solis-Lozano L, Suarez-Alvarez K, Gonzalez-Chavez A, Bejar YL, Robles-Diaz G, et al. Hyperleptinemia is associated with parameters of low-grade systemic inflammation and metabolic dysfunction in obese human beings. Front Integr Neurosci. 2013;7:62. doi:10.3389/fnint.2013.00062.
17. Zahran WE, Salah El-Dien KA, Kamel PG, El-Sawaby AS. Efficacy of tumor necrosis factor and interleukin-10 analysis in the follow-up of nonalcoholic fatty liver disease progression. Indian J Clin Biochem. 2013;28(2):141–6. doi:10.1007/s12291-012-0236-5.
18. Rumack CWS, Charboneau W. Diagnostic ultrasound. 2nd ed. St Louis: Mosby; 1998.
19. Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation. 2004;109(3):433–8. doi:10.1161/01.CIR.0000111245.75752.C6.
20. Rosas-Guzmán J G-CA, Aschner P, Bastarrachea P. Consenso Latinoamericano de la Asociación Latinoamericana de Diabetes (ALAD) Epidemiología, Diagnóstico, Control, Prevención y Tratamiento del Síndrome Metabólico en Adultos. Consensos ALAD. 2010.
21. Luo W, Guo Z, Wu M, Hao C, Zhou Z, Yao X. Index of central obesity as a parameter to replace waist circumference for the definition of metabolic syndrome in predicting cardiovascular disease. J Cardiovasc Med (Hagerstown). 2014;15(10):738–44. doi:10.2459/JCM.0000000000000039.
22. Tiehuis AM, van der Graaf Y, Mali WP, Vincken K, Muller M, Geerlings MI. Metabolic syndrome, prediabetes, and brain abnormalities on MRI in patients with manifest arterial disease: the SMART-MR study. Diabetes Care. 2014;37(9):2515–21. doi:10.2337/dc14-0154.
23. Segula D. Complications of obesity in adults: a short review of the literature. Malawi Med J. 2014;26(1):20–4.
24. Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends in obesity among US adults, 1999–2000. JAMA. 2002;288(14):1723–7.
25. Dietz WH, Robinson TN. Clinical practice. Overweight children and adolescents. N Engl J Med. 2005;352(20):2100–9. doi:10.1056/NEJMcp043052.
26. Chitturi S, Farrell GC. Etiopathogenesis of nonalcoholic steatohepatitis. Semin Liver Dis. 2001;21(1):27–41.
27. McFarlin BK, Johnson CA, Moreno JP, Foreyt JP. Mexican American children have differential elevation of metabolic biomarkers proportional to obesity status. J Pediatr Gastroenterol Nutr. 2013;57(6):718–21. doi:10.1097/MPG.0b013e3182a6993d.
28. Invitti C, Maffeis C, Gilardini L, Pontiggia B, Mazzilli G, Girola A, et al. Metabolic syndrome in obese Caucasian children: prevalence using WHO-derived criteria and association with nontraditional cardiovascular risk factors. Int J Obes (Lond). 2006;30(4):627–33. doi:10.1038/sj.ijo.0803151.
29. Rizzo AC, Goldberg TB, Silva CC, Kurokawa CS, Nunes HR, Corrente JE. Metabolic syndrome risk factors in overweight, obese, and extremely obese Brazilian adolescents. Nutr J. 2013;12:19. doi:10.1186/1475-2891-12-19.
30. Barbarroja N, Lopez-Pedrera R, Mayas MD, Garcia-Fuentes E, Garrido-Sanchez L, Macias-Gonzalez M, et al. The obese healthy paradox: is inflammation the answer? Biochem J. 2010;430(1):141–9. doi:10.1042/BJ20100285.
31. Goday A, Benaiges D, Parri A, Ramon JM, Flores-Le Roux JA, Pedro Botet J. Can bariatric surgery improve cardiovascular risk factors in the metabolically healthy but morbidly obese patient? Surg Obes Relat Dis. 2014;. doi:10.1016/j.soard.2014.04.022.
32. Jimenez A, Perea V, Corcelles R, Moize V, Lacy A, Vidal J. Metabolic effects of bariatric surgery in insulin-sensitive morbidly obese subjects. Obes Surg. 2013;23(4):494–500. doi:10.1007/s11695-012-0817-7.
33. Bluher M. Are there still healthy obese patients? Curr Opin Endocrinol Diabetes Obes. 2012;19(5):341–6. doi:10.1097/MED.0b013e328357f0a3.
34. Angulo P. GI epidemiology: nonalcoholic fatty liver disease. Aliment Pharmacol Ther. 2007;25(8):883–9. doi:10.1111/j.1365-2036.2007.03246.x.
35. Sims EA. Are there persons who are obese, but metabolically healthy? Metabolism. 2001;50(12):1499–504. doi:10.1053/meta.2001.27213.
36. de la Cruz-Munoz N, Messiah SE, Arheart KL, Lopez-Mitnik G, Lipshultz SE, Livingstone A. Bariatric surgery significantly decreases the prevalence of type 2 diabetes mellitus and pre-diabetes among morbidly obese multiethnic adults: long-term results. J Am Coll Surg. 2011;212(4):505–11; discussion 12–3. doi:10.1016/j.jamcollsurg.2010.12.015.
37. Koh KK, Han SH, Quon MJ. Inflammatory markers and the metabolic syndrome: insights from therapeutic interventions. J Am Coll Cardiol. 2005;46(11):1978–85. doi:10.1016/j.jacc.2005.06.082.
38. Hayashino Y, Jackson JL, Hirata T, Fukumori N, Nakamura F, Fukuhara S, et al. Effects of exercise on C-reactive protein, inflammatory cytokine and adipokine in patients with type 2 diabetes: a meta-analysis of randomized controlled trials. Metabolism. 2014;63(3):431–40. doi:10.1016/j.metabol.2013.08.018.
39. Esser N, Legrand-Poels S, Piette J, Scheen AJ, Paquot N. Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes. Diabetes Res Clin Pract. 2014;105(2):141–50. doi:10.1016/j.diabres.2014.04.006.
40. DeMarco VG, Johnson MS, Whaley-Connell AT, Sowers JR. Cytokine abnormalities in the etiology of the cardiometabolic syndrome. Curr Hypertens Rep. 2010;12(2):93–8. doi:10.1007/s11906-010-0095-5.
41. Gotoh K, Inoue M, Shiraishi K, Masaki T, Chiba S, Mitsutomi K, et al. Spleen-derived interleukin-10 downregulates the severity of high-fat diet-induced non-alcoholic fatty pancreas disease. PLoS ONE. 2012;7(12):e53154. doi:10.1371/journal.pone.0053154.
42. Yekollu SK, Thomas R, O’Sullivan B. Targeting curcusomes to inflammatory dendritic cells inhibits NF-kappaB and improves insulin resistance in obese mice. Diabetes. 2011;60(11):2928–38. doi:10.2337/db11-0275.
43. Chuang CC, McIntosh MK. Potential mechanisms by which polyphenol-rich grapes prevent obesity-mediated inflammation and metabolic diseases. Annu Rev Nutr. 2011;31:155–76. doi:10.1146/annurev-nutr-072610-145149.
44. Liu Y, Dang H, Li D, Pang W, Hammock BD, Zhu Y. Inhibition of soluble epoxide hydrolase attenuates high-fat-diet-induced hepatic steatosis by reduced systemic inflammatory status in mice. PLoS ONE. 2012;7(6):e39165. doi:10.1371/journal.pone.0039165.
45. Fierbinteanu-Braticevici C, Baicus C, Tribus L, Papacocea R. Predictive factors for nonalcoholic steatohepatitis (NASH) in patients with nonalcoholic fatty liver disease (NAFLD). J Gastrointestin Liver Dis. 2011;20(2):153–9.
46. Pappo I, Bercovier H, Berry E, Gallilly R, Feigin E, Freund HR. Antitumor necrosis factor antibodies reduce hepatic steatosis during total parenteral nutrition and bowel rest in the rat. J Parenter Enteral Nutr. 1995;19(1):80–2.
47. Seki S, Kitada T, Sakaguchi H. Clinicopathological significance of oxidative cellular damage in non-alcoholic fatty liver diseases. Hepatol Res. 2005;33(2):132–4. doi:10.1016/j.hepres.2005.09.020.
48. Higuchi H, Gores GJ. Mechanisms of liver injury: an overview. Curr Mol Med. 2003;3(6):483–90.
49. Jaeschke H, Gores GJ, Cederbaum AI, Hinson JA, Pessayre D, Lemasters JJ. Mechanisms of hepatotoxicity. Toxicol Sci. 2002;65(2):166–76.
50. Budick-Harmelin N, Dudas J, Demuth J, Madar Z, Ramadori G, Tirosh O. Triglycerides potentiate the inflammatory response in rat Kupffer cells. Antioxid Redox Signal. 2008;10(12):2009–22. doi:10.1089/ars.2007.1876.
51. Seth RK, Das S, Kumar A, Chanda A, Kadiiska MB, Michelotti G, et al. CYP2E1-dependent and leptin-mediated hepatic CD57 expression on CD8+ T cells aid progression of environment-linked nonalcoholic steatohepatitis. Toxicol Appl Pharmacol. 2014;274(1):42–54. doi:10.1016/j.taap.2013.10.029.
52. Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest. 2002;109(9):1125–31. doi:10.1172/JCI15593.
53. Roden M. Mechanisms of disease: hepatic steatosis in type 2 diabetes—pathogenesis and clinical relevance. Nat Clin Pract Endocrinol Metab. 2006;2(6):335–48. doi:10.1038/ncpendmet0190.
54. Saraiva M, O’Garra A. The regulation of IL-10 production by immune cells. Nat Rev Immunol. 2010;10(3):170–81. doi:10.1038/nri2711.
55. Rabelo F, Oliveira CP, Faintuch J, Mazo DF, Lima VM, Stefano JT, et al. Pro- and anti-inflammatory cytokines in steatosis and steatohepatitis. Obes Surg. 2010;20(7):906–12. doi:10.1007/s11695-010-0181-4.
56. Cintra DE, Pauli JR, Araujo EP, Moraes JC, de Souza CT, Milanski M, et al. Interleukin-10 is a protective factor against diet-induced insulin resistance in liver. J Hepatol. 2008;48(4):628–37. doi:10.1016/j.jhep.2007.12.017.
57. Zhou DS, Liang ZQ, Qin Q, Zhang MH, Li SL. Therapeutic efficacy and mechanisms of quercetin in a rat model of nonalcoholic fatty liver disease. Zhonghua Gan Zang Bing Za Zhi. 2013;21(2):134–7. doi:10.3760/cma.j.issn.1007-3418.2013.02.014.
58. den Boer MA, Voshol PJ, Schroder-van der Elst JP, Korsheninnikova E, Ouwens DM, Kuipers F, et al. Endogenous interleukin-10 protects against hepatic steatosis but does not improve insulin sensitivity during high-fat feeding in mice. Endocrinology. 2006;147(10):4553–8. doi:10.1210/en.2006-0417.
59. Wang Y, Li YY, Nie YQ, Zhou YJ, Cao CY, Xu L. Association between metabolic syndrome and the development of non-alcoholic fatty liver disease. Exp Ther Med. 2013;6(1):77–84. doi:10.3892/etm.2013.1090.
60. Shima T, Seki K, Umemura A, Ogawa R, Horimoto R, Oya H, et al. Influence of lifestyle-related diseases and age on the development and progression of non-alcoholic fatty liver disease. Hepatol Res. 2014;. doi:10.1111/hepr.12384.
61. Wang Z, Xu M, Peng J, Jiang L, Hu Z, Wang H, et al. Prevalence and associated metabolic factors of fatty liver disease in the elderly. Exp Gerontol. 2013;48(8):705–9. doi:10.1016/j.exger.2013.05.059.
62. Mocchegiani E, Costarelli L, Giacconi R, Malavolta M, Basso A, Piacenza F, et al. Vitamin E-gene interactions in aging and inflammatory age-related diseases: implications for treatment. A systematic review. Ageing Res Rev. 2014;14:81–101. doi:10.1016/j.arr.2014.01.001.
63. Arutyunyan TV, Korystova AF, Kublik LN, Levitman M, Shaposhnikova VV, Korystov YN. Effects of taxifolin on the activity of angiotensin-converting enzyme and reactive oxygen and nitrogen species in the aorta of aging rats and rats treated with the nitric oxide synthase inhibitor and dexamethasone. Age (Dordr). 2013;35(6):2089–97. doi:10.1007/s11357-012-9497-4.
64. Kozina LS, Borzova IV, Arutiunov VA, Ryzhak GA. The role of oxidative stress in skin aging. Adv Gerontol. 2012;25(2):217–22.